Integrated analysis of proteome and transcriptome profiling reveals pan-cancer-associated pathways and molecular biomarkers DOI Creative Commons

Guo‐sheng Hu,

Zaozao Zheng,

Yaohui He

et al.

Molecular & Cellular Proteomics, Journal Year: 2025, Volume and Issue: unknown, P. 100919 - 100919

Published: Jan. 1, 2025

Language: Английский

The phosphatase PP1 sustains global transcription by promoting RNA polymerase II pause release DOI
Zhenning Wang, Aixia Song,

Bolin Tao

et al.

Molecular Cell, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 1, 2024

Language: Английский

Citations

7
Chemical inhibitors of transcription-associated kinases DOI Creative Commons

Kevin C. Clopper,

Dylan J. Taatjes

Current Opinion in Chemical Biology, Journal Year: 2022, Volume and Issue: 70, P. 102186 - 102186

Published: Aug. 1, 2022

Transcription by RNA polymerase II (pol II) is regulated kinases. In recent years, many selective and potent inhibitors of pol transcription-associated kinases have been developed, these molecules advanced understanding kinase function in mammalian cells. Here, we focus on chemical the CDK7, CDK8, CDK9, CDK12, CDK13, CDK19. We provide a brief overview common activation mechanisms. then highlight advantages compared with other basic research methods, describe caveats associated non-selective compounds (e.g. flavopiridol). conclude strategies recommendations for implementation experimental analysis

Language: Английский

Citations

26
Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive breast cancer revealed by single-cell RNA sequencing DOI Creative Commons
Fang Jia, Shanshan Sun, Jiaxin Li

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: 585, P. 216656 - 216656

Published: Jan. 23, 2024

Hormone receptor-positive breast cancer (HR

Language: Английский

Citations

6
Transcription factors-related molecular subtypes and risk prognostic model: exploring the immunogenicity landscape and potential drug targets in hepatocellular carcinoma DOI Creative Commons
Meixia Wang,

Hanyao Guo,

Bo Zhang

et al.

Cancer Cell International, Journal Year: 2024, Volume and Issue: 24(1)

Published: Jan. 4, 2024

Abstract Background Hepatocellular carcinoma (HCC) is the most prevalent form of liver cancer, with a high mortality rate and poor prognosis. Mutated or dysregulated transcription factors (TFs) are significantly associated carcinogenesis. The aim this study was to develop TF-related prognostic risk model predict prognosis guide treatment HCC patients. Methods RNA sequencing data were obtained from TCGA database. ICGC GEO databases used as validation datasets. consensus clustering algorithm classify molecular subtypes TFs. Kaplan‒Meier survival analysis receiver operating characteristic (ROC) applied evaluate value model. immunogenic landscape differences evaluated by TIMER xCell algorithms. Autodock possible binding sites trametinib RT‒PCR verify effect on expression core Results According differential TFs, samples divided into two clusters (C1 C2). time, signaling pathways, abundance immune cell infiltration responses chemotherapy immunotherapy different between C1 C2. Nine TFs potential value, including HMGB2, ESR1, HMGA1, MYBL2, TCF19, E2F1, FOXM1, CENPA ZIC2, identified Cox regression analysis. patients in high-risk group had compared those low-risk ( p < 0.001). Moreover, area under ROC curve (AUC) values 1-year, 2-year 3-year rates 0.792, 0.71 0.695, respectively. validated Notably, sensitivity highly correlated docking predicted these More importantly, downregulated treatment. Conclusions A signature 9 performed well predicting chemotherapy/immunotherapy Trimetinib has application targeting

Language: Английский

Citations

5
Activation of Bivalent Gene POU4F1 Promotes and Maintains Basal‐like Breast Cancer DOI Creative Commons
Jiahui Zhang,

Nanyan Miao,

Liyan Lao

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: 11(20)

Published: March 16, 2024

Abstract Basal‐like breast cancer (BLBC) is the most aggressive molecular subtype of with worse prognosis and fewer treatment options. The underlying mechanisms upon BLBC transcriptional dysregulation its upstream transcription factors (TFs) remain unclear. Here, among hyperactive candidate TFs identified by bioinformatic analysis, POU4F1 uniquely upregulated in associated poor prognosis. necessary for tumor growth malignant phenotypes through regulating G1/S transition direct binding at promoter CDK2 CCND1. More importantly, maintains identity repressing ERα expression CDK2‐mediated EZH2 phosphorylation subsequent H3K27me3 modification ESR1 promoter. Knocking out cells reactivates functional expression, rendering sensitive to tamoxifen treatment. In‐depth epigenetic analysis reveals that subtype‐specific re‐configuration activation bivalent chromatin contributes unique BLBC, which maintained DNA demethylase TET1. Together, these results reveal a epigenetically activated TF critical role promoting maintaining suggesting potential therapeutic target BLBC.

Language: Английский

Citations

5
Emerging role of MYB transcription factors in cancer drug resistance DOI Open Access
Bernhard Biersack, Michael Höpfner

Cancer Drug Resistance, Journal Year: 2024, Volume and Issue: unknown

Published: April 30, 2024

Decades ago, the viral myeloblastosis oncogene v -myb was identified as a gene responsible for development of avian leukemia. However, relevance MYB proteins human cancer diseases, in particular solid tumors, remained basically unrecognized very long time. The family transcription factors comprises (c-MYB), MYBL2 (b-MYB), and MYBL1 (a-MYB), which are overexpressed several cancers associated with progression resistance to anticancer drugs. In addition overexpression, presence activated MYB-fusion tumor drivers described certain cancers. identification drug mediated by their underlying mechanisms great importance understanding failures current therapies establishing new more efficient therapy regimens. addition, candidates targeting factor activity signaling have emerged promising class potential therapeutics that could tackle MYB-dependent drug-resistant selective way. This review describes correlation formation persistence various approved investigational

Language: Английский

Citations

5
Regulations of m6A and other RNA modifications and their roles in cancer DOI
Xinhui Chen,

Kunxiong Guo,

Jing Li

et al.

Frontiers of Medicine, Journal Year: 2024, Volume and Issue: 18(4), P. 622 - 648

Published: June 22, 2024

Language: Английский

Citations

5
Targeting CDK7 in oncology: The avenue forward DOI
Zhimei Li, Guan Liu, Ya Gao

et al.

Pharmacology & Therapeutics, Journal Year: 2022, Volume and Issue: 240, P. 108229 - 108229

Published: June 11, 2022

Language: Английский

Citations

20
A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022) DOI Creative Commons
Markéta Kovalová,

Joseph Peter Baraka,

Václav Mik

et al.

Expert Opinion on Therapeutic Patents, Journal Year: 2023, Volume and Issue: 33(2), P. 67 - 87

Published: Feb. 1, 2023

Introduction Cyclin-dependent kinase 7 (CDK7) is a member of the CDK family serine/threonine protein kinases and participates in regulation cell cycle mRNA transcription. CDK7 emerging as possible drug target oncology six exciting candidates have already undergone early evaluation clinical trials.Areas covered This review examines inhibitors anticancer drugs reported patents published online databases World Intellectual Property Organization European Patent Office 2018-2022 period. provides an overview available inhibitors, including their chemical structures, biochemical profile stage development.Expert opinion Small-molecule represent attractive pharmacological modalities for treatment various cancer types. Highly potent selective been discovered many them show promising results several preclinical models. Developed compounds act on by mechanisms, traditional ATP competition, irreversible binding to tractable cysteine 312 outside active site CDK7, induced degradation proteolysis targeting chimeras. Ongoing research trials should reveal which strategy will provide highest benefits.

Language: Английский

Citations

12
The function of LncRNA-ATB in cancer DOI
Amir Anbiyaiee, Mohammad Ramazii,

Siamak Soltani Bajestani

et al.

Clinical & Translational Oncology, Journal Year: 2022, Volume and Issue: 25(1), P. 1 - 9

Published: May 21, 2022

Language: Английский

Citations

18